5PSQ-092 Treatment of metastatic HER2+ breast cancer: use of trastuzumab biosimilars in combination with pertuzumab | European Journal of Hospital Pharmacy

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via EAHP

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via EAHP

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

Section 5: Patient safety and quality assurance

5PSQ-092 Treatment of metastatic HER2+ breast cancer: use of trastuzumab biosimilars in combination with pertuzumab

Free

Online download statistics by month:

Online download statistics by month: March 2022 to September 2024

	Abstract	Full	Pdf
Mar 2022	42	0	2
Apr 2022	40	0	1
May 2022	7	0	3
Jun 2022	18	0	0
Jul 2022	27	0	2
Aug 2022	12	0	3
Sep 2022	19	0	2
Oct 2022	14	0	0
Nov 2022	16	0	2
Dec 2022	30	0	8
Jan 2023	16	0	1
Feb 2023	10	0	4
Mar 2023	8	0	1
Apr 2023	8	0	1
May 2023	2	0	0
Jul 2023	8	0	2
Aug 2023	2	0	1
Sep 2023	30	0	4
Oct 2023	1	0	1
Nov 2023	13	0	1
Dec 2023	10	0	4
Jan 2024	4	0	3
Feb 2024	4	0	2
Mar 2024	18	0	1
Apr 2024	8	0	3
May 2024	15	0	0
Jun 2024	10	0	0
Jul 2024	6	0	3
Aug 2024	6	0	3
Sep 2024	11	0	3
Total	415	0	61